Journal
BIOLOGICAL & PHARMACEUTICAL BULLETIN
Volume 41, Issue 5, Pages 828-833Publisher
PHARMACEUTICAL SOC JAPAN
DOI: 10.1248/bpb.b18-00046
Keywords
selenoprotein P; monoclonal antibody; enzyme-linked immunosorbent assay (ELISA); sol particle homogeneous immunoassay (SPIA); commercially available kit
Categories
Funding
- KAKENHI Grant from the Japan Society for the Promotion of Science (JSPS) [25292078, 17H03821]
- Ministry of Education, Culture, Sports, Science and Technology (MEXT) [25292078, 17H03821]
- Grants-in-Aid for Scientific Research [17H03821] Funding Source: KAKEN
Ask authors/readers for more resources
Selenoprotein P (SeP) is a selenium (Se)-rich extracellular protein. SeP is identified as a hepatokine, causing insulin resistance in type 2 diabetes. Thus, the measurement of SeP in serum has received much attention, and several enzyme-linked immunosorbent assay (ELISA) kits for SeP determination are now commercially available. In the present study, we determined the serum SeP levels by our original ELISA and sol particle homogeneous immunoassay (SPIA) methods and also by commercially available kits, and these determinants were compared. We found a kit-dependent correlation of the determinants with our methods. These results suggest that the selection of kit is critical for comparison with our previous reports and for discussing the relationship between the serum SeP levels and disease condition.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available